CBIO
Crescent Biopharma, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$571.90M
P/E Ratio
—
EPS
$-5.88
Beta
—
52W High
$27.41
52W Low
$8.72
50-Day MA
$18.27
200-Day MA
$13.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Crescent Biopharma, Inc.
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, is focused on developing candidates for protease products in the fields of hemostasis and complement regulation. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $11.88M |
| Gross Profit (TTM) | $11.88M |
| EBITDA | $-152.55M |
| Operating Margin | -2380.00% |
| Return on Equity | -160.70% |
| Return on Assets | -69.20% |
| Revenue/Share (TTM) | $0.59 |
| Book Value | $5.41 |
| Price-to-Book | 3.17 |
| Price-to-Sales (TTM) | 48.13 |
| EV/Revenue | 32.51 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $27.57M |
| Float | $14.60M |
| % Insiders | 5.81% |
| % Institutions | 96.16% |
Historical Volatility
HV 10-Day
82.01%
HV 20-Day
112.80%
HV 30-Day
110.77%
HV 60-Day
101.67%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($30.29 target)
1
Strong Buy8
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026